Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’
The Pharma Data
MAY 5, 2021
. Affinia Therapeutics raises $110 million for gene therapy treatments ( STAT ). New variant-hardy AbCellera-Lilly mAb shows utility of viral genomics surveillance ( BioCentury ). Startup sets out to tackle the gene therapy manufacturing crisis ( Endpoints ). Medtech.
52 
Let's personalize your content